News & Updates

Bladder catheterization route among adolescents and young adults with spina bifida does not seem to contribute significantly to health-related quality of life (QOL), reveals a study.

Neoadjuvant exercise therapy may be beneficial in the treatment of men with prostate cancer, with a dose of 225 min per week showing a promising activity against the disease, as shown in the results of a phase Ia nonrandomized, dose-finding study.

Overactive bladder (OAB) is common among women undergoing menopause, especially among those at late menopausal stage and who have other menopausal symptoms, as reported in a cross-sectional study.

New drug applications approved by US FDA as of 16-30 June 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

The use of the alpha-1 adrenergic receptor antagonists (alpha-blockers) terazosin, doxazosin, and alfuzosin—medications for benign prostate hyperplasia (BPH)—may help reduce the incidence of dementia with Lewy bodies (DLB) in men, as suggested in a study.

Among people who have undergone stone surgery, those with a history of bowel resection and bypass appear to be at increased risk of repeat stone surgery, according to a study.

The combination of avelumab and cisplatin-based chemotherapy as neoadjuvant therapy for MIUC yields high OS and EFS rates at both 1 and 3 years, according to the survival data from the dual-cohort, phase II AURA trial presented at ASCO 2024